824 related articles for article (PubMed ID: 36712951)
1. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.
Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P
Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.
Boekel L; Stalman EW; Wieske L; Hooijberg F; van Dam KPJ; Besten YR; Kummer LYL; Steenhuis M; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Vogelzang EH; Leeuw M; Atiqi S; van Vollenhoven R; Gerritsen M; van der Horst-Bruinsma IE; Lems WF; Nurmohamed MT; Boers M; Keijzer S; Keijser J; van de Sandt C; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Rispens T; Kuijpers TW; Wolbink G; Eftimov F;
Lancet Rheumatol; 2022 Jun; 4(6):e417-e429. PubMed ID: 35527808
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 breakthrough infections in rheumatic diseases patients after vaccination.
Alshukairi AN; Al-Omari A; Albeity A; Alandijany TA; Hassan AM; El-Kafrawy SA; Dada A; Al Hroub MK; El-Saed A; Bissar LS; Daghmush RM; Al-Ghamdi SMG; Perlman S; Azhar EI; Halabi H
J Infect Public Health; 2022 Jun; 15(6):685-688. PubMed ID: 35623243
[TBL] [Abstract][Full Text] [Related]
7. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Liu Z; Le K; Zhou X; Alexander JL; Lin S; Bewshea C; Chanchlani N; Nice R; McDonald TJ; Lamb CA; Sebastian S; Kok K; Lees CW; Hart AL; Pollok RC; Boyton RJ; Altmann DM; Pollock KM; Goodhand JR; Kennedy NA; Ahmad T; Powell N;
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):145-156. PubMed ID: 36481043
[TBL] [Abstract][Full Text] [Related]
8. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study.
Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S
Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.
Liew J; Gianfrancesco M; Harrison C; Izadi Z; Rush S; Lawson-Tovey S; Jacobsohn L; Ja C; Hyrich KL; Gossec L; Strangfeld A; Carmona L; Schäfer M; Frãzao-Mateus E; Bulina I; Stafford F; Tufan A; Graver C; Yardımcı GK; Zepa J; Al Emadi S; Cook C; Abutiban F; Dey D; Katigbak G; Kaufman L; Kowalski E; Martínez-Martínez MU; Patel NJ; Reyes-Cordero G; Salido E; Smith E; Snow D; Sparks J; Wise L; Bhana S; Gore-Massy M; Grainger R; Hausmann J; Sirotich E; Sufka P; Wallace Z; Machado PM; Robinson PC; Yazdany J
RMD Open; 2022 Apr; 8(1):. PubMed ID: 35387864
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
13. Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases.
Papagoras C; Zioga N; Papadopoulos V; Gerolymatou N; Kalavri E; Bounos C; Simopoulou T; Fragoulis GE; Panopoulos S; Fragiadaki K; Evangelatos G; Bournia VK; Arida A; Karamanakos A; Pappa M; Kravvariti E; Deftereou K; Kougkas N; Zampeli E; Kataxaki E; Melissaropoulos K; Barouta G; Panagiotopoulos A; Koutsianas C; Liossis SN; Georgiou P; Dimitroulas T; Tektonidou MG; Bogdanos DP; Elezoglou A; Voulgari PV; Sfikakis PP; Vassilopoulos D
Clin Rheumatol; 2023 Dec; 42(12):3375-3385. PubMed ID: 37731083
[TBL] [Abstract][Full Text] [Related]
14. Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons With Breakthrough Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a High-Risk National Population.
Butt AA; Yan P; Shaikh OS; Mayr FB; Omer SB
Clin Infect Dis; 2022 Aug; 75(1):e849-e856. PubMed ID: 34893812
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.
Hall VJ; Foulkes S; Saei A; Andrews N; Oguti B; Charlett A; Wellington E; Stowe J; Gillson N; Atti A; Islam J; Karagiannis I; Munro K; Khawam J; Chand MA; Brown CS; Ramsay M; Lopez-Bernal J; Hopkins S;
Lancet; 2021 May; 397(10286):1725-1735. PubMed ID: 33901423
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
Molteni E; Canas LS; Kläser K; Deng J; Bhopal SS; Hughes RC; Chen L; Murray B; Kerfoot E; Antonelli M; Sudre CH; Pujol JC; Polidori L; May A; Hammers PA; Wolf J; Spector PTD; Steves CJ; Ourselin PS; Absoud M; Modat M; Duncan PEL
Lancet Reg Health Eur; 2022 Aug; 19():100429. PubMed ID: 35821715
[TBL] [Abstract][Full Text] [Related]
18. Profiling post-COVID-19 condition across different variants of SARS-CoV-2: a prospective longitudinal study in unvaccinated wild-type, unvaccinated alpha-variant, and vaccinated delta-variant populations.
Canas LS; Molteni E; Deng J; Sudre CH; Murray B; Kerfoot E; Antonelli M; Rjoob K; Capdevila Pujol J; Polidori L; May A; Österdahl MF; Whiston R; Cheetham NJ; Bowyer V; Spector TD; Hammers A; Duncan EL; Ourselin S; Steves CJ; Modat M
Lancet Digit Health; 2023 Jul; 5(7):e421-e434. PubMed ID: 37202336
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
